International Headache Society Committee on Clinical Trials in Migraine.Guidelines for controlled trials of drugs in migraine. First edition.Cephalalgia1991;
11:
1–12
2.
FerrariMD311C90: Increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists.Neurology1997;
48Suppl 3:
S21–4
3.
GeraudGOlesonJPfaffenrathVTfelt-HansenPZuppingRSweetRthe multinational oral zolmitriptan and sumatriptan comparative study groupComparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design.
Cephalalgia
(forthcoming)
4.
DahlöfCDienerHCGoadsbyPJMassiouHOlesenJSchoenenJZolmitriptan a 5HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study.Eur J Neurol1998;
5:
535–43
5.
RapoportAMRamadanNMAdelmannJUMathewNTElkindAHKudrowDBOptimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose-finding study.Neurology1997;
49:
1210–8
6.
SolomonGDCadyRKKlapperJAEarlNLSaperJRRamadanNMbehalf of the 042 Clinical Trial Study GroupClinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine.Neurology1997;
9:
1219–25
7.
Tfelt-HansenPEfficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment. A systematic review based on numbers needed to treat.Cephalalgia1998;
18:
532–8
